KYORIN Pharmaceutical Co., Ltd. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
No of Months
12
12
12
12
12
12
Profit Before Tax
12,770.00
7,239.00
6,906.00
5,216.00
8,352.00
8,255.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-12,636.00
-5,995.00
-9,056.00
-1,673.00
-2,880.00
-2,132.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
3,506.00
1,549.00
2,008.00
6,346.00
5,189.00
7,739.00
Cash Flow from Investing Activities
-6,323.00
-3,187.00
-6,275.00
-2,560.00
-4,259.00
-2,943.00
Cash Flow from Financing Activities
3,952.00
-3,347.00
-3,363.00
-4,112.00
-4,918.00
-5,117.00
Net Cash Inflow / Outflow
1,135.00
-4,898.00
-7,389.00
-187.00
-4,031.00
-343.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
87.00
241.00
139.00
-43.00
-22.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in JPY Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of KYORIN Pharmaceutical Co., Ltd.
Figures in Million
consolidated Cash Flow Results
Change(JPY)
Change(%)
Profit Before Tax
12770
-14950
27,720.00
185.42%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-12636
-1557
-11,079.00
-711.56%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
3506
-2668
6,174.00
231.41%
Cash Flow from Investing Activities
-6323
5430
-11,753.00
-216.45%
Cash Flow from Financing Activities
3952
-16028
19,980.00
124.66%
Net Cash Inflow / Outflow
1135
-11904
13,039.00
109.53%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
1362
-1,362.00
-100.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 126.34% vs -22.86% in Mar 2024
Mar'25
Mar'24
Change(%)
Cash Flow from Operating Activities
3,506.00
1,549.00
126.34%






